{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:40:32Z","timestamp":1788212432698,"version":"build-2803163510"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FIU Embrace"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions.<\/jats:p>\n              <jats:p>This paper analyzed recent peer-reviewed literature to identify the current state of evidence regarding cannabis use for the ASD population. Systematic reviews, reports, and experimental studies were assessed to understand the current extent and nature of the evidence on the risks and benefits of cannabis use for ASD. At this time, three large-scale clinical trials are currently at varying stages of progress and publication of results. Only five small studies were identified that have specifically examined cannabis use in ASD. Given the sparse state of evidence directly assessed in this population, studies which examined effects of cannabis on\u00a0shared pathological symptoms of ASD such as\u00a0hyperactivity, sleep disorders, self-injury, anxiety, behavioral problems, and communication\u00a0were also reviewed.<\/jats:p>\n              <jats:p>Studies revealed mixed and inconclusive findings of cannabis effects for all conditions, except epilepsy. Adverse outcomes were also reported, which included severe psychosis, increased agitation, somnolence, decreased appetite, and irritability. In addition, a wide range of cannabis compositions and dosage were identified within the studies, which impact generalizability.<\/jats:p>\n              <jats:p>There is currently insufficient evidence for cannabis use in ASD, which creates  an urgent need for additional large-scale controlled studies to increase understanding of risks and benefits and also to\u00a0examine the impact of \u201centourage effects.\u201d This will support discussions of treatment options between health care providers and ASD patients\u00a0and their families. Evidence may lead to a desired new line of treatment or prevent adverse outcomes from unsubstantiated use amongst families aiming for symptom reduction.<\/jats:p>","DOI":"10.1186\/s12888-019-2259-4","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:44:43Z","timestamp":1572468283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Current state of evidence of cannabis utilization for treatment of autism spectrum disorders"],"prefix":"10.1186","volume":"19","author":[{"given":"Rumi","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-3536","authenticated-orcid":false,"given":"Shanna L.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlaina","family":"Maddux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"2259_CR1","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;42:180\u20138.","journal-title":"Pharm Ther"},{"key":"2259_CR2","doi-asserted-by":"publisher","DOI":"10.17226\/24625","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. \n                    https:\/\/doi.org\/10.17226\/24625\n                    \n                  ."},{"key":"2259_CR3","unstructured":"Little B. Why the U.S. made marijuana illegal. History. 2017. \n                    https:\/\/www.history.com\/news\/why-the-u-s-made-marijuana-illegal\n                    \n                  . Accessed 11 Jan 2019."},{"key":"2259_CR4","doi-asserted-by":"publisher","unstructured":"Good CB, Parekh N, Manolis C, Shrank W, Fischer K. Brief commentary: treating pain\u2014the cannabis conundrum. Ann Intern Med. 2019. \n                    https:\/\/doi.org\/10.7326\/M18-3237\n                    \n                  .","DOI":"10.7326\/M18-3237"},{"key":"2259_CR5","first-page":"732","volume":"16","author":"J Gregario","year":"2014","unstructured":"Gregario J. Physicians, medical marijuana, and the law. Am Med Assoc J Ethics. 2014;16:732\u20138.","journal-title":"Am Med Assoc J Ethics"},{"key":"2259_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","volume":"163","author":"EB Russo","year":"2011","unstructured":"Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344\u201364.","journal-title":"Br J Pharmacol"},{"key":"2259_CR7","volume-title":"Marijuana as medicine","author":"National Institute on Drug Abuse","year":"2017","unstructured":"National Institute on Drug Abuse. Marijuana as medicine. 2017. \n                    https:\/\/www.drugabuse.gov\/publications\/drugfacts\/marijuana-medicine\n                    \n                  . Accessed 3 Jul 2017."},{"key":"2259_CR8","doi-asserted-by":"publisher","unstructured":"Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2019;9. \n                    https:\/\/doi.org\/10.3389\/fphar.2018.01521\n                    \n                  .","DOI":"10.3389\/fphar.2018.01521"},{"key":"2259_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.yebeh.2016.09.040","volume":"70","author":"EB Russo","year":"2017","unstructured":"Russo EB. Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy Behav. 2017;70:292\u20137.","journal-title":"Epilepsy Behav"},{"key":"2259_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejmech.2018.07.076","volume":"157","author":"T Nuutinen","year":"2018","unstructured":"Nuutinen T. Medicinal properties of terpenes found in cannabis sativa and humulus lupulus. Eur J Med Chem. 2018;157:198\u2013228.","journal-title":"Eur J Med Chem"},{"key":"2259_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/head.13345","volume":"58","author":"EP Baron","year":"2018","unstructured":"Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache J Head Face Pain. 2018;58:1139\u201386.","journal-title":"Headache J Head Face Pain"},{"key":"2259_CR12","volume-title":"National center for complementary and integrative health","author":"Marijuana and Cannabinoids","year":"2018","unstructured":"Marijuana and Cannabinoids. National center for complementary and integrative health. 2018. \n                    https:\/\/nccih.nih.gov\/health\/marijuana\n                    \n                  . Accessed 10 Jan 2019."},{"key":"2259_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2018.01.003","volume":"49","author":"DI Abrams","year":"2018","unstructured":"Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the national academies of sciences, engineering and medicine report. Eur J Intern Med. 2018;49:7\u201311.","journal-title":"Eur J Intern Med"},{"key":"2259_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA MacCallum","year":"2018","unstructured":"MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12\u20139.","journal-title":"Eur J Intern Med"},{"key":"2259_CR15","unstructured":"Centers for Disease Control and Prevention. Data and statistics autism spectrum disorder (ASD): Centers for disease control and prevention; 2018. \n                    https:\/\/www.cdc.gov\/ncbddd\/autism\/data.html\n                    \n                  . Accessed 11 Jan 2019"},{"key":"2259_CR16","first-page":"1","volume":"2","author":"B Gu","year":"2017","unstructured":"Gu B. Cannabidiol provides viable treatment opportunity for multiple neurological pathologies of autism spectrum disorder. Glob Drugs Ther. 2017;2:1\u20134.","journal-title":"Glob Drugs Ther"},{"key":"2259_CR17","first-page":"2165","volume":"10","author":"D Siniscalco","year":"2013","unstructured":"Siniscalco D. Current findings and research prospective in autism spectrum disorders. Autism. 2013;10:2165.","journal-title":"Autism"},{"key":"2259_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/can.2015.0008","volume":"1","author":"D Wei","year":"2016","unstructured":"Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res. 2016;1:81\u20139.","journal-title":"Cannabis Cannabinoid Res"},{"key":"2259_CR19","first-page":"1","volume":"5","author":"CA Salgado","year":"2018","unstructured":"Salgado CA, Castellanos D. Autism spectrum disorder and cannabidiol: have we seen this movie before? Glob Pediatr Health. 2018;5:1\u20135.","journal-title":"Glob Pediatr Health"},{"key":"2259_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2018.08.023","volume":"88","author":"VD Kidd","year":"2018","unstructured":"Kidd VD. Cannabinoids in the treatment of autism spectrum disorder: demanding data before using fad therapies. Pediatr Neurol. 2018;88:10\u20131.","journal-title":"Pediatr Neurol"},{"key":"2259_CR21","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/febs.12260","volume":"280","author":"P Pacher","year":"2013","unstructured":"Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease: successes and failures. FEBS J. 2013;280:1918\u201343.","journal-title":"FEBS J"},{"key":"2259_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","volume":"12","author":"B Chakrabarti","year":"2015","unstructured":"Chakrabarti B, Persico A, Battista N, Maccarrone M. Endocannabinoid signaling in autism. Neurotherapeutics. 2015;12:837\u201347.","journal-title":"Neurotherapeutics"},{"key":"2259_CR23","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1523\/JNEUROSCI.0795-10.2010","volume":"30","author":"L Zhang","year":"2010","unstructured":"Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci. 2010;30:5724\u20139.","journal-title":"J Neurosci"},{"key":"2259_CR24","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/npp.2010.19","volume":"35","author":"M Maccarrone","year":"2010","unstructured":"Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, et al. Abnormal mGlu 5 receptor\/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacol. 2010;35:1500\u20139.","journal-title":"Neuropsychopharmacol"},{"key":"2259_CR25","doi-asserted-by":"publisher","first-page":"e17073","DOI":"10.1371\/journal.pone.0017073","volume":"6","author":"S Pietropaolo","year":"2011","unstructured":"Pietropaolo S, Guilleminot A, Martin B, D\u2019Amato FR, Crusio WE. Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice. PLoS One. 2011;6:e17073.","journal-title":"PLoS One"},{"key":"2259_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/ncomms2045","volume":"3","author":"K-M Jung","year":"2012","unstructured":"Jung K-M, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080.","journal-title":"Nat Commun"},{"key":"2259_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prostaglandins.2008.12.002","volume":"89","author":"J Wang","year":"2009","unstructured":"Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 2009;89:112\u20139.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2259_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tins.2007.12.005","volume":"31","author":"DG Amaral","year":"2008","unstructured":"Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci. 2008;31:137\u201345.","journal-title":"Trends Neurosci"},{"key":"2259_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1601-183X.2007.00330.x","volume":"7","author":"HG McFarlane","year":"2008","unstructured":"McFarlane HG, Kusek GK, Yang M, Phoenix JL, Bolivar VJ, Crawley JN. Autism-like behavioral phenotypes in BTBR T+tf\/J mice. Genes Brain Behav. 2008;7:152\u201363.","journal-title":"Genes Brain Behav"},{"key":"2259_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/npp.2009.201","volume":"35","author":"JL Silverman","year":"2010","unstructured":"Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacol. 2010;35:976\u201389.","journal-title":"Neuropsychopharmacol"},{"key":"2259_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/157015911795017047","volume":"9","author":"ES Onaivi","year":"2011","unstructured":"Onaivi ES, Benno R, Halpern T, Mehanovic M, Schanz N, Sanders C, et al. Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Curr Neuropharmacol. 2011;9:209\u201314.","journal-title":"Curr Neuropharmacol"},{"key":"2259_CR32","doi-asserted-by":"publisher","first-page":"e62189","DOI":"10.1371\/journal.pone.0062189","volume":"8","author":"SM McTighe","year":"2013","unstructured":"McTighe SM, Neal SJ, Lin Q, Hughes ZA, Smith DG. The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. PLoS One. 2013;8:e62189.","journal-title":"PLoS One"},{"key":"2259_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbr.2008.09.041","volume":"197","author":"R Benno","year":"2009","unstructured":"Benno R, Smirnova Y, Vera S, Liggett A, Schanz N. Exaggerated responses to stress in the BTBR T+tf\/J mouse: an unusual behavioral phenotype. Behav Brain Res. 2009;197:462\u20135.","journal-title":"Behav Brain Res"},{"key":"2259_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.neuron.2013.02.036","volume":"78","author":"C F\u00f6ldy","year":"2013","unstructured":"F\u00f6ldy C, Malenka RC, S\u00fcdhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78:498\u2013509.","journal-title":"Neuron"},{"key":"2259_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nn.2720","volume":"14","author":"V Di Marzo","year":"2011","unstructured":"Di Marzo V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat Neurosci. 2011;14:9\u201315.","journal-title":"Nat Neurosci"},{"key":"2259_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.pharmthera.2010.10.006","volume":"129","author":"C Li","year":"2011","unstructured":"Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther. 2011;129:307\u201320.","journal-title":"Pharmacol Ther"},{"key":"2259_CR37","unstructured":"Stone J, Bogner C. The endocannabinoid system as it relates to autism. \n                    https:\/\/www.scribd.com\/document\/218971076\/The-Endocannabinoid-System-as-it-Relates-to-Autism\n                    \n                  . Accessed 3 Jul 2017."},{"key":"2259_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","volume":"249","author":"DM Kerr","year":"2013","unstructured":"Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res. 2013;249:124\u201332.","journal-title":"Behav Brain Res"},{"key":"2259_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ntt.2013.01.004","volume":"36","author":"FI Roullet","year":"2013","unstructured":"Roullet FI, Lai JKY, Foster JA. In utero exposure to valproic acid and autism \u2014 a current review of clinical and animal studies. Neurotoxicol Teratol. 2013;36:47\u201356.","journal-title":"Neurotoxicol Teratol"},{"key":"2259_CR40","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1007\/s10803-013-1824-9","volume":"43","author":"D Siniscalco","year":"2013","unstructured":"Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord. 2013;43:2686\u201395.","journal-title":"J Autism Dev Disord"},{"key":"2259_CR41","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/j.1460-9568.2006.04697.x","volume":"23","author":"B Chakrabarti","year":"2006","unstructured":"Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci. 2006;23:1944\u20138.","journal-title":"Eur J Neurosci"},{"key":"2259_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.euroneuro.2008.05.003","volume":"18","author":"K Domschke","year":"2008","unstructured":"Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol. 2008;18:751\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2259_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3934\/molsci.2019.1.27","volume":"6","author":"S Schultz","year":"2019","unstructured":"Schultz S, Siniscalco D. Endocannabinoid system involvement in autism spectrum disorder: an overview with potential therapeutic applications. AIMS Mol Sci. 2019;6:27\u201337.","journal-title":"AIMS Mol Sci"},{"key":"2259_CR44","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037\u201343.","journal-title":"Neurochem Res"},{"issue":"Suppl 1","key":"2259_CR45","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/schbul\/sby014.068","volume":"44","author":"JA Crippa","year":"2018","unstructured":"Crippa JA, Zuardi AW, Guimaraes FS. Possible mechanisms involved in the antipsychotic effects of cannabidiol (CBD). Schizophr Bull. 2018;44(Suppl 1):S28.","journal-title":"Schizophr Bull"},{"key":"2259_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","volume":"480","author":"M van der Stelt","year":"2003","unstructured":"van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol. 2003;480:133\u201350.","journal-title":"Eur J Pharmacol"},{"key":"2259_CR47","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/j.1755-5949.2010.00144.x","volume":"16","author":"J Fern\u00e1ndez-Ruiz","year":"2010","unstructured":"Fern\u00e1ndez-Ruiz J, Hern\u00e1ndez M, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16:e72\u201391.","journal-title":"CNS Neurosci Ther"},{"key":"2259_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nm.3127","volume":"19","author":"A Busquets-Garcia","year":"2013","unstructured":"Busquets-Garcia A, Gomis-Gonz\u00e1lez M, Guegan T, Agust\u00edn-Pav\u00f3n C, Pastor A, Mato S, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med. 2013;19:603\u20137.","journal-title":"Nat Med"},{"key":"2259_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacother J Hum Pharmacol Drug Ther. 2013;33:195\u2013209.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2259_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/aps.2016.149","volume":"38","author":"D Chen","year":"2017","unstructured":"Chen D, Gao M, Gao F, Su Q, Wu J. Brain cannabinoid receptor 2: expression, function and modulation. Acta Pharmacol Sin. 2017;38:312\u20136.","journal-title":"Acta Pharmacol Sin"},{"key":"2259_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1742-2094-11-78","volume":"11","author":"D Siniscalco","year":"2014","unstructured":"Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N. The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. J Neuroinflammation. 2014;11:78.","journal-title":"J Neuroinflammation"},{"key":"2259_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lfs.2019.03.053","volume":"224","author":"M Premoli","year":"2019","unstructured":"Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina SD, et al. Cannabidiol: recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019;224:120\u20137.","journal-title":"Life Sci"},{"key":"2259_CR53","volume-title":"NIH. U.S. National Library of Medicine","author":"Medical Cannabis Registry and Pharmacology","year":"2018","unstructured":"Medical Cannabis Registry and Pharmacology. NIH. U.S. National Library of Medicine. 2018. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03699527\n                    \n                  . Accessed 4 Jan 2019."},{"key":"2259_CR54","unstructured":"Shifting brain excitation-inhibition balance in autism spectrum disorder. NIH. U.S. National Library of Medicine. 2018. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03537950\n                    \n                  . Accessed 4 Jan 2019."},{"key":"2259_CR55","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","volume":"44","author":"CM Pretzsch","year":"2019","unstructured":"Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44:1398.","journal-title":"Neuropsychopharmacology"},{"key":"2259_CR56","unstructured":"Cannabinoids for behavioral problems in children with ASD. NIH. U.S. National Library of Medicine. 2018. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02956226\n                    \n                  . Accessed 4 Jan 2019."},{"key":"2259_CR57","unstructured":"Arditi L. After other options fail, a family tries medical marijuana for son with autism. Morning Edition. 2018. \n                    https:\/\/www.npr.org\/sections\/health-shots\/2018\/12\/25\/679830133\/after-other-options-fail-a-family-tries-medical-marijuana-for-son-with-autism\n                    \n                  . Accessed 4 Jan 2019."},{"key":"2259_CR58","unstructured":"Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD). NIH. U.S. National Library of Medicine. 2018. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03202303\n                    \n                  . Accessed 4 Jan 2019."},{"key":"2259_CR59","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","volume":"9","author":"L Bar-Lev Schleider","year":"2019","unstructured":"Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9:200.","journal-title":"Sci Rep"},{"key":"2259_CR60","doi-asserted-by":"publisher","unstructured":"Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: Cannabidiol-rich cannabis in children with autism Spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study. J Autism Dev Disord. 2018. \n                    https:\/\/doi.org\/10.1007\/s10803-018-3808-2\n                    \n                  .","DOI":"10.1007\/s10803-018-3808-2"},{"key":"2259_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/1362361315593941","volume":"20","author":"M Chowdhury","year":"2016","unstructured":"Chowdhury M, Aman MG, Lecavalier L, Smith T, Johnson C, Swiezy N, et al. Factor structure and psychometric properties of the revised home situations questionnaire for autism spectrum disorder: the home situations questionnaire-autism Spectrum disorder. Autism Int J Res Pract. 2016;20:528\u201337.","journal-title":"Autism Int J Res Pract"},{"key":"2259_CR62","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10803-011-1274-1","volume":"42","author":"LMT Silva","year":"2012","unstructured":"Silva LMT, Schalock M. Autism parenting stress index: initial psychometric evidence. J Autism Dev Disord. 2012;42:566\u201374.","journal-title":"J Autism Dev Disord"},{"key":"2259_CR63","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","volume":"167","author":"BH King","year":"2013","unstructured":"King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism Spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013;167:1045\u201352.","journal-title":"JAMA Pediatr"},{"key":"2259_CR64","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jns.2017.08.2623","volume":"381","author":"G Kuester","year":"2017","unstructured":"Kuester G, Vergara K, Ahumada A, Gazmuri AM. Oral cannabis extracts as a promising treatment for the core symptoms of autism spectrum disorder: preliminary experience in Chilean patients. J Neurol Sci. 2017;381:932\u20133.","journal-title":"J Neurol Sci"},{"key":"2259_CR65","unstructured":"Guy W, National Institute of Mental Health (U.S.). Psychopharmacology Research Branch. Division of Extramural Research Programs. ECDEU assessment manual for psychopharmacology. Rockville, Md. : U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. \n                    http:\/\/archive.org\/details\/ecdeuassessmentm1933guyw\n                    \n                  . Accessed 22 Jul 2019."},{"key":"2259_CR66","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485\u201391.","journal-title":"Am J Ment Defic"},{"key":"2259_CR67","first-page":"4","volume":"5","author":"R Kurz","year":"2010","unstructured":"Kurz R, Blaas K. Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids. 2010;5:4\u20136.","journal-title":"Cannabinoids"},{"key":"2259_CR68","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","volume":"89","author":"S Poleg","year":"2019","unstructured":"Poleg S, Golubchik P, Offen D, Weizman A. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2019;89:90\u20136.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2259_CR69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-0037-1598109","volume":"15","author":"CL Anderson","year":"2017","unstructured":"Anderson CL, Evans VF, DeMarse TB, Febo M, Johnson CR, Carney PR. Cannabidiol for the treatment of drug-resistant epilepsy in children: current state of research. J Pediatr Neurol. 2017;15:143\u201350.","journal-title":"J Pediatr Neurol"},{"key":"2259_CR70","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.yebeh.2016.12.032","volume":"70","author":"D Sulak","year":"2017","unstructured":"Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017;70:328\u201333.","journal-title":"Epilepsy Behav"},{"key":"2259_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.yebeh.2016.11.016","volume":"70","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70:313\u20138.","journal-title":"Epilepsy Behav"},{"key":"2259_CR72","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.yebeh.2017.02.005","volume":"70","author":"AS Suraev","year":"2017","unstructured":"Suraev AS, Todd L, Bowen MT, Allsop DJ, McGregor IS, Ireland C, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017;70:334\u201340.","journal-title":"Epilepsy Behav"},{"key":"2259_CR73","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4103\/1817-1745.174438","volume":"10","author":"PA Devnani","year":"2015","unstructured":"Devnani PA, Hegde AU. Autism and sleep disorders. J Pediatr Neurosci. 2015;10:304\u20137.","journal-title":"J Pediatr Neurosci"},{"key":"2259_CR74","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456\u201373.","journal-title":"JAMA"},{"key":"2259_CR75","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.smrv.2014.02.005","volume":"18","author":"PJ Gates","year":"2014","unstructured":"Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev. 2014;18:477\u201387.","journal-title":"Sleep Med Rev"},{"key":"2259_CR76","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.jcp.0000125688.05091.8f","volume":"24","author":"AN Nicholson","year":"2004","unstructured":"Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of \u0394-9-tetrahydrocannabinol and Cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24:305\u201313.","journal-title":"J Clin Psychopharmacol"},{"key":"2259_CR77","doi-asserted-by":"crossref","unstructured":"Richards C, Moss J, Nelson L, Oliver C. Persistence of self-injurious behaviour in autism spectrum disorder over 3 years: A prospective cohort study of risk markers. J of Neurodev Disord. 2016;8:21.","DOI":"10.1186\/s11689-016-9153-x"},{"key":"2259_CR78","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-Na\u00efve social phobia patients. Neuropsychopharmacology. 2011;36:1219\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"2259_CR79","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jamapsychiatry.2015.3229","volume":"73","author":"C Blanco","year":"2016","unstructured":"Blanco C, Hasin DS, Wall MM, Fl\u00f3rez-Salamanca L, Hoertel N, Wang S, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA Psychiatry. 2016;73:388\u201395.","journal-title":"JAMA Psychiatry"},{"key":"2259_CR80","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.euroneuro.2015.12.037","volume":"26","author":"D Feingold","year":"2016","unstructured":"Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and anxiety disorders: results from a population-based representative sample. Eur Neuropsychopharmacol. 2016;26:493\u2013505.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2259_CR81","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ajmg.a.35754","volume":"161","author":"A Sagar","year":"2013","unstructured":"Sagar A, Bishop JR, Tessman DC, Guter S, Martin CL, Cook EH. Co-occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion. Am J Med Genet A. 2013;161:845\u20139.","journal-title":"Am J Med Genet A"},{"key":"2259_CR82","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2017","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2017;175:225\u201331.","journal-title":"Am J Psychiatry"},{"key":"2259_CR83","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.biopsych.2015.07.024","volume":"79","author":"T Rubino","year":"2016","unstructured":"Rubino T, Parolaro D. The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol Psychiatry. 2016;79:578\u201385.","journal-title":"Biol Psychiatry"},{"key":"2259_CR84","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1001\/jama.2015.6407","volume":"313","author":"DC D\u2019Souza","year":"2015","unstructured":"D\u2019Souza DC, Ranganathan M. Medical marijuana: is the cart before the horse? JAMA. 2015;313:2431\u20132.","journal-title":"JAMA"},{"key":"2259_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.15288\/jsad.2014.75.211","volume":"75","author":"D De Alwis","year":"2014","unstructured":"De Alwis D, Agrawal A, Reiersen AM, Constantino JN, Henders A, Martin NG, et al. ADHD symptoms, autistic traits, and substance use and misuse in adult Australian twins. J Stud Alcohol Drugs. 2014;75:211\u201321.","journal-title":"J Stud Alcohol Drugs"},{"key":"2259_CR86","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27:795\u2013808.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2259_CR87","first-page":"12","volume":"14","author":"KL Harrison","year":"2017","unstructured":"Harrison KL, Zane T. Focus on science: is there science behind that?: autism and treatment with marijuana. Sci Autism Treat. 2017;14:12\u20135.","journal-title":"Sci Autism Treat"},{"key":"2259_CR88","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1111\/bcp.13695","volume":"84","author":"LM Dryburgh","year":"2018","unstructured":"Dryburgh LM, Bolan NS, Grof CPL, Galettis P, Schneider J, Lucas CJ, et al. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol. 2018;84:2468\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"2259_CR89","doi-asserted-by":"publisher","first-page":"15493","DOI":"10.1038\/ncomms15493","volume":"8","author":"M Arora","year":"2017","unstructured":"Arora M, Reichenberg A, Willfors C, Austin C, Gennings C, Berggren S, et al. Fetal and postnatal metal dysregulation in autism. Nat Commun. 2017;8:15493.","journal-title":"Nat Commun"},{"key":"2259_CR90","doi-asserted-by":"publisher","first-page":"e20180558","DOI":"10.1542\/peds.2018-0558","volume":"143","author":"SW Duvall","year":"2019","unstructured":"Duvall SW, Lindly O, Zuckerman K, Msall ME, Weddle M. Ethical implications for providers regarding Cannabis use in children with autism Spectrum disorders. Pediatrics. 2019;143:e20180558.","journal-title":"Pediatrics."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-019-2259-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:17:54Z","timestamp":1603844274000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1186\/s12888-019-2259-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SLB has received research grants from FIU Embrace, the Florida Department of Health, University of Central Florida \/ Department of Education, the Dan Marino Foundation, and the Neuroscience Centers of Florida Foundation. RA and MM were funded by FIU Embrace to serve as graduate research assistants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"328"}}